All the news Showing 1 of 1 articles from: NASHGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Emricasan and selonsertib fail to improve fibrosis in people with NASH Liz Highleyman / 12 November 2019 A pair of experimental therapies for non-alcoholic steatohepatitis (NASH) failed to offer notable improvements in controlled clinical trials, despite having shown promising effects on liver biomarkers in earlier studies. Dr Stephen Harrison ... ← First1Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD NASH Experimental treatments for NASH/NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive